Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEZSCVE:GPHNASDAQ:MDNACVE:WMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEZSAeterna Zentaris$3.35+0.8%$3.46$3.96▼$12.00$6.01M1.557,305 shs1,390 shsGPHGraphite OneC$0.71-2.7%C$0.82C$0.55▼C$1.07C$71.89M1.0271,907 shs142,724 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsWMDWeedMDC$0.28-1.8%C$0.28C$0.23▼C$0.99C$67.82MN/A766,591 shs271,436 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEZSAeterna Zentaris+0.75%-6.11%-5.63%+8.94%-27.80%GPHGraphite One-2.74%-5.33%-22.83%-25.26%+4.41%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%WMDWeedMD0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEZSAeterna ZentarisN/AN/AN/AN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna Therapeutics1.2163 of 5 stars3.50.00.00.00.01.70.0WMDWeedMDN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEZSAeterna Zentaris 0.00N/AN/AN/AGPHGraphite One 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideWMDWeedMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEZSAeterna Zentaris$2.37M2.53N/AN/A$14.99 per share0.22GPHGraphite OneN/AN/AC$0.01 per share94.17C$0.44 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AWMDWeedMDC$27.53M2.46C$0.08 per share3.27C$0.34 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEZSAeterna Zentaris-$16.55M-$14.86N/A∞N/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)GPHGraphite One-C$4.90M-C$0.07N/A∞N/AN/A-10.96%-6.61%N/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/AWMDWeedMDN/A-C$0.42N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEZSAeterna ZentarisN/AN/AN/AN/AN/AGPHGraphite OneN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AWMDWeedMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEZSAeterna ZentarisN/A5.945.93GPHGraphite One0.021.090.33MDNAMedicenna TherapeuticsN/A9.579.57WMDWeedMD95.633.461.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEZSAeterna Zentaris0.73%GPHGraphite One0.07%MDNAMedicenna Therapeutics12.38%WMDWeedMDN/AInsider OwnershipCompanyInsider OwnershipAEZSAeterna Zentaris0.10%GPHGraphite One28.81%MDNAMedicenna Therapeutics33.10%WMDWeedMDN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEZSAeterna Zentaris201.79 million1.79 millionNo DataGPHGraphite One20101.25 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableWMDWeedMD628246.62 millionN/ANot OptionableAEZS, GPH, MDNA, and WMD HeadlinesRecent News About These CompaniesENTG:CA Entourage Health Corp.October 19, 2024 | seekingalpha.comHurricane Helene by the numbers: Catastrophic destruction covers 400 milesOctober 4, 2024 | abcnews.go.comWMDH WMD Holdings Group, Inc.September 27, 2024 | seekingalpha.comEthics and Weapons of Mass DestructionAugust 8, 2024 | cambridge.orgC'Truth about WMD will finally emerge'March 4, 2024 | dailymail.co.ukNo cabinet submission on costs, benefits, implications of going to war in IraqJanuary 3, 2024 | theaustralian.com.auBlair: 'Saddam still has weapons of mass destruction'October 4, 2023 | dailymail.co.ukBush administration retreats on WMD claimAugust 29, 2023 | namibian.com.naNMissing WMD ‘hurting war on terror’August 29, 2023 | namibian.com.naNWeapons of Mass Destruction and the ethics of their usageAugust 17, 2023 | arstechnica.comARussia used sabotaged dam as ‘weapon of mass destruction’ says UkraineJune 12, 2023 | politico.euPUS, South Korea issue fresh North Korea sanctions on 'illicit' IT workforceMay 27, 2023 | asahi.comAMalaysia Gets Tough on WMDMay 27, 2023 | thediplomat.comTInterpol Tackles WMD TerrorismMay 21, 2023 | thediplomat.comT'Weapons of mass destruction found'May 20, 2023 | dailymail.co.ukChemical Weapons are NOT WMDsMay 17, 2023 | thediplomat.comTThe Next Financial WMD?May 14, 2023 | thestreet.comThe Week in Weed – May 6, 2023 - StratCannMay 6, 2023 | news.google.comNWMD in Iraq: Evidence and ImplicationsApril 28, 2023 | medscape.comMWhat happened when WMD experts tried to make the GPT-4 AI do bad thingsApril 1, 2023 | thebulletin.orgTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEZS, GPH, MDNA, and WMD Company DescriptionsAeterna Zentaris NASDAQ:AEZS$3.35 +0.03 (+0.75%) As of 06/25/2025Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Graphite One CVE:GPHC$0.71 -0.02 (-2.74%) As of 06/26/2025 03:59 PM EasternGraphite One Inc. operates as mineral exploration company in the United States. The company holds interest in the Graphite Creek property that consists of 135 mining claims located on the Seward Peninsula, Alaska. The company was formerly known as Graphite One Resources Inc. and changed its name to Graphite One Inc. in February 2019. Graphite One Inc. was incorporated in 2006 and is headquartered in Vancouver, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.WeedMD CVE:WMDC$0.28 -0.01 (-1.79%) As of 07/15/2021WeedMD Inc. produces, distributes, and sells medical-grade cannabis in Canada. It offers dried cannabis, cannabis plants and seeds, cannabis oil, edibles, extracts and topicals, and others, as well as cannabis flower products. The company sells its products directly to medical patients and strategic relationships across the seniors' market, as well as through supply agreements with Shoppers Drug Mart and six provincial distribution agencies under the Color Cannabis, Saturday, Starseed, and WeedMD brand names. WeedMD Inc. is headquartered in Aylmer, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
